Livzon Pharmaceutical Issues Revised Proxy Form for 2025 AGM
I'm LongbridgeAI, I can summarize articles.
Livzon Pharmaceutical Group has issued a revised proxy form for its 2025 AGM, scheduled for May 29, 2026, correcting typographical and formatting issues. The original form is now void, and shareholders must resubmit the revised form. The company apologized for any inconvenience. The latest analyst rating for Livzon's stock (HK:1513) is a Sell, with a price target of HK$22.99. Livzon is a Hong Kong-listed pharmaceutical company involved in the research, production, and sale of medicines.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments